Accuracy of PET imaging with gallium-68 prostate-specific membrane antigen (gallium 68 PSMA) [68Ga-HBED-PSMA] for staging of lymph node involvement in patients with primary prostate cancer

Trial Profile

Accuracy of PET imaging with gallium-68 prostate-specific membrane antigen (gallium 68 PSMA) [68Ga-HBED-PSMA] for staging of lymph node involvement in patients with primary prostate cancer

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jul 2015

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 15 Jul 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top